Exploring Endotypes in Chronic Rhinosinusitis (ExpRess): Protocol for a cohort study
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0289407 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift PLOS ONE, 2023. Verfasst von Shyam Ajay Gokani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Rhinology and ENT Research Group, Norwich Medical School, University of East Anglia, Norwich, United Kingdom. Hauptthemen laut MEDLINE: Rhinitis, Sinusitis, Nasal Polyps. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Health, Biotechnology and Biological Sciences Research Council, University of East Anglia.
Abstract (Originalsprache)
Background
Chronic Rhinosinusitis (CRS) affects approximately 1 in 10 UK adults and impacts quality of life quality of life significantly. Response to treatment may be driven by individual CRS endotypes and therefore work to delineate biomarker clusters that may separate responders from non-responders is needed. The ongoing MACRO three-arm parallel-group trial randomises adult CRS patients to endoscopic sinus surgery, macrolide therapy or placebo.
Aim
This study aims to correlate CRS endotypes with clinical parameters from the ongoing MACRO trial, including olfactory function and outcomes in terms of response to treatment using core biomarkers sets.
Methods
Adult CRS patients enrolled into the MACRO trial will be recruited from participating UK otorhinolaryngology departments. Nasal tissue samples and swabs will be obtained in theatre or clinic from patients randomised to all three trial arms. Nasal tissue will be analysed with multiplex electrochemiluminescence for 32 cytokines including IL-5, IL-13, IgE and periostin. Bacterial swabs will be analysed using illumina miSeq 16S amplicon sequencing. Mean expression for each biomarker will be reported for treatment responder and non-responder groups. Correlation of biomarkers with MACRO trial outcome data such as endoscopic evaluation scores and quality-of-life improvement scores will be reported.
Discussion
Defining clear endotypes in CRS will contribute to refining patient pathways for the efficient use of clinical resources. This work may lay the groundwork for future studies to predict which patients might respond to medical or surgical therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Rhinology and ENT Research Group, Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
- Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
- Quadram Institute Bioscience, Norwich, United Kingdom.
- Department of Otolaryngology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
ORCID-Profile: Shyam Ajay Gokani, Carl Philpott
Förderung
- Department of Health
- Biotechnology and Biological Sciences Research Council
- University of East Anglia
- ENT UK
- NIHR
Zitieren
APA
Gokani, S. A., Jefferson, M., Gavrilovic, J., Clark, A., Hildebrand, F., Wileman, T., Hopkins, C., & Philpott, C. (2023). Exploring Endotypes in Chronic Rhinosinusitis (ExpRess): Protocol for a cohort study. PLOS ONE. https://doi.org/10.1371/journal.pone.0289407
Vancouver
Gokani SA, Jefferson M, Gavrilovic J, Clark A, Hildebrand F, Wileman T, et al. Exploring Endotypes in Chronic Rhinosinusitis (ExpRess): Protocol for a cohort study. PLOS ONE. 2023. doi:10.1371/journal.pone.0289407
BibTeX
@article{Gokani2023,
author = {Gokani, Shyam Ajay and Jefferson, Matthew and Gavrilovic, Jelena and Clark, Allan and Hildebrand, Falk and Wileman, Tom and Hopkins, Claire and Philpott, Carl},
title = {Exploring Endotypes in Chronic Rhinosinusitis (ExpRess): Protocol for a cohort study},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0289407}
}
EUVIMED